- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03321838
Office Based Vergence and Accommodative Therapy and Intermittent Exotropia
Pilot Study of Office Based Vergence and Accommodative Therapy as Treatment of Intermittent Exotropia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All enrolled px received 16-20 sessions of OBVAT, 60 minutes per visit, one time per week; Home reinforcement, 15 minutes each time, five times per week.
- Primary outcome measure: A. Change in the office based intermittent exotropia control score
- Secondary outcome measures A. Change in Look And Cover, then Ten seconds of Observation Scale for Exotropia (LACTOSE) B. Change in Newcastle Control Score (NCS) C. Change in Chinese intermittent exotropia questionnaire (CIXTQ) D. Change in near stereopsis by Preschool randot near stereoacuity E. Change in size of distant deviation angle by prism alternating cover test F. Change in size of near deviation angle by prism alternating cover test
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Zhongshan Ophthalmic Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 8 to 18 years old
- deviation meeting all of the following criteria: A. intermittent or constant exotropia at distance (mean of 3 baseline assessments of distance control> or = Grade 2) B. intermittent exotropia at near (at least 1 of 3 assessments of near control at the baseline visit Grade 2-4) C. distance and near exodeviation both between 15 to 35 prism diopters (PD) measured by prism and alternate cover test (PACT); D. near deviation not exceeding the distance deviation by >10PD by PACT (i.e., convergence insufficiency type IXT excluded)
- cycloplegic objective refraction spherical equivalent (SE) refractive error between -6.00 diopters (D)and +1.00 D inclusive in either eye
Patients must be wearing the updated refractive correction (spectacles or contact lenses) for at least 1 week if refractive error (based on cycloplegic refraction performed within 6 months) meets any of the following:
A. Myopia >-0.50 D spherical equivalent in either eye B. Anisometropia >1.00 D spherical equivalent C. Astigmatism in either eye >1.50 D
Refractive correction must meet the following guidelines:
A. Anisometropia spherical equivalent must be within 0.25 D of the full anisometropic difference B. Astigmatism cylinder must be within 0.25 D of full correction and axis must be within 5 degree C. For hyperopia and myopia, the spherical component can be reduced by investigator discretion provided reduction is symmetrical and results in residual (i.e., uncorrected) spherical equivalent refractive error that does not exceed +1.50 D spherical equivalent hyperopia or -0.50 D spherical equivalent myopia
- Gestational age >34 weeks
- Birth weight >1500 g
- No previous surgical or nonsurgical treatment for IXT other than single vision refractive correction (e.g. PALs, Bifocals, patching, or deliberate over-minus with spectacles more than 0.50 D)
- No vision therapy or orthoptics for any reason within the last year
- No prior strabismus surgery or botulinum injection, intraocular surgery, or refractive surgery
- No strabismus surgery planned
- vision correctable to at least 20/25 or better at distance and near in each eye.
- Px needs to have a computer at home which can connect to internet
Exclusion Criteria:
- Patient with nystagmus, restrictive or paretic strabismus
- Patient with amblyopia, which is defined as >or = 0.2 logarithm of the minimum angle of resolution units of interocular difference and > or = 0.3 logarithm of the minimum angle of resolution units in one eye ( Variability of stereoacuity in intermittent exotropia)
- Regular use of any ocular or systemic medications known to affect accommodation or vergence system, such as atropine, pirenzepine, and anti-epileptic medications in recent 3 months;
- developmental disability, attention deficit hyperactivity disorder(ADHD), or learning disability diagnosis in children that in the investigator's discretion would interfere with office-based treatment;
- Relocation anticipated for 2 years;
- Significant ocular or neurologic disorders (e.g. cerebral palsy) other than strabismus
- Vertical deviation greater than 1 pd in cover test
- Household member already in the study.
- Any eye care professional, ophthalmic technician, medical student, or optometry student
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Accommodative/vergence therapy
Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group.
These therapy includes accommodative, vergence and anti-suppression technique.
No drug is used during the whole therapy process.
|
Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group.
These therapy includes accommodative, vergence and anti-suppression technique.
No drug is used during the whole therapy process.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Office based intermittent exotropia control score
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Office based intermittent exotropia control score is an office based score to assess the control of intermittent exotropia.
Minimum score is 0 (best score, phoria) and Maximum score is 5(worst score, constant tropia).
Change in Office based intermittent exotropia control score after 14 weeks of vision therapy
|
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Look And Cover, then Ten seconds of Observation Scale for Exotropia(LACTOSE)
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Look And Cover, then Ten seconds of Observation Scale for Exotropia (LACTOSE) is an office based score to assess the control of intermittent exotropia.
Minimum score is 0 (best score, phoria) and Maximum score is 4(worst score, constant tropia).
Change in score after 14 weeks of vision therapy.
|
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
|
Newcastle Control Score
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Newcastle Control Score is an office based and home based score to assess the control of intermittent exotropia.
Minimum score is 0 (best score) and Maximum score is 6(worst score).
Change in score after 14 weeks of vision therapy.Change in score after 14 weeks of vision therapy.
|
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
|
Chinese intermittent exotropia questionnaire
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Change in Chinese intermittent exotropia questionnaire after 14 weeks of vision therapy.
|
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
|
Preschool randot near stereoacuity
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Change in near stereopsis by Preschool randot near stereoacuity after 14 weeks of vision therapy.
|
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
|
deviation angle
Time Frame: Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Change in size of distant deviation angle by prism alternating cover test after 14 weeks of vision therapy.
|
Baseline visit, 7th visit(7 weeks after BL), 15th visit (15 weeks after BL)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chen xiang, associate chief physician
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XT1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intermittent Exotropia
-
Universitat Politècnica de CatalunyaHospital Universitari Mútua de TerrassaNot yet recruitingExotropia Intermittent | Intermittent Strabismus | Esotropia Intermittent
-
Retina Foundation of the SouthwestRecruiting
-
Yonsei UniversityCompletedExotropia or Intermittent ExotropiaKorea, Republic of
-
Nunaps IncCompletedIntermittent ExotropiaSouth Korea
-
Retina Foundation of the SouthwestActive, not recruiting
-
Singapore National Eye CentreTerminatedIntermittent ExotropiaSingapore
-
Indiana University School of MedicineTerminatedIntermittent ExotropiaUnited States
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupCompletedIntermittent ExotropiaUnited States
-
Samsung Medical CenterCompletedIntermittent Exotropia
-
Benha UniversityCompletedIntermittent ExotropiaEgypt
Clinical Trials on accommodative/vergence therapy
-
Salus UniversityUniversity of Alabama at Birmingham; National Eye Institute (NEI); Ohio State... and other collaboratorsUnknownConvergence InsufficiencyUnited States
-
Sun Yat-sen UniversityUnknown
-
Sun Yat-sen UniversityUnknown
-
Salus UniversityNot yet recruiting
-
Sun Yat-sen UniversitySalus UniversityNot yet recruitingIntermittent Exotropia
-
New Jersey Institute of TechnologyChildren's Hospital of Philadelphia; National Eye Institute (NEI); Rutgers University and other collaboratorsCompletedMild Traumatic Brain Injury | Concussion, Mild | Convergence Insufficiency | Concussion; Eye | Persistent Post-concussive SymptomsUnited States
-
New Jersey Institute of TechnologyNational Eye Institute (NEI)CompletedConvergence InsufficiencyUnited States
-
Salus UniversityUnknownConvergence InsufficiencyUnited States
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Pediatric Eye Disease Investigator GroupCompleted
-
Midwestern UniversitySouthern California College of Optometry at Marshall B. Ketchum University; New Jersey Institute of Technology and other collaboratorsRecruitingConvergence InsufficiencyUnited States